Lisa Ryden
Experienced in Menopause

Lisa Ryden

Medicon Village, 
Lund, M, SE 
Experienced in Menopause
Medicon Village, 
Lund, M, SE 
OverviewLocationsClinical Research

Overview

Lisa Ryden practices in Lund, Sweden. Ms. Ryden is rated as an Experienced expert by MediFind in the treatment of Menopause. Her top areas of expertise are Breast Cancer, Menopause, Cerebral Hypoxia, Mastectomy, and Tissue Biopsy.

Her clinical research consists of co-authoring 165 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 18 articles in the study of Menopause.

Gender
Female

Locations

Medicon Village, Lund, M 22381, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Survival and Axillary Recurrence Following Sentinel Node-positive Breast Cancer Without Completion Axillary Lymph Node Dissection - a Randomized Study of Patients With Macrometastases in the Sentinel Node
Survival and Axillary Recurrence Following Sentinel Node-positive Breast Cancer Without Completion Axillary Lymph Node Dissection - a Randomized Study of Patients With Macrometastases in the Sentinel Node
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
Survival and Axillary Relapse in Breast Cancer Patients With Sentinel Node Micrometastases Who Have Not Undergone Completion Axillary Clearance - a National Cohort Study
Survival and Axillary Relapse in Breast Cancer Patients With Sentinel Node Micrometastases Who Have Not Undergone Completion Axillary Clearance - a National Cohort Study
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Added Value of Contrast Enhanced Spectral Mammography, CESM in Diagnostics and Size Estimation of Malignant Lesions in Breast. A Pilot Study.
Added Value of Contrast Enhanced Spectral Mammography, CESM in Diagnostics and Size Estimation of Malignant Lesions in Breast. A Pilot Study.
Enrollment Status: Completed
Publish Date: January 18, 2019
Intervention Type: Diagnostic test
Study Phase: Not Applicable
View 2 Less Clinical Trials

165 Total Publications

Myeloperoxidase expressing tumor associated neutrophils are associated with worse prognosis in metastatic breast cancer patients.
Myeloperoxidase expressing tumor associated neutrophils are associated with worse prognosis in metastatic breast cancer patients.
Journal: Scientific reports
Published: March 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Ryden's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile